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1. Introduction
  Extended-spectrum-毬-lactamases (ESBLs) are 
enzymes produced by Gram negative bacteria which were 
first described in the 1980s. They have been detected 
in Klebsiella species, and sufbsequently in Escherichia 
coli (E. coli) , Pseudomonas aeruginosa (P. aeruginosa) 
, Serratia marcescens (S. marcescens) and other Gram-
negative bacilli which have emerged as a significant 
mechanism of resistance to oxyimino-cephalosporin 
antibiotics during the last 2 decades[1]. The resistance to 
broad-spectrum cephalosporins and aztreonam is mostly 
mediated by 毬-lactamases by hydrolyzing the 毬-lactam 
ring[2]. The ESBL’s genes are usually found on plasmids, 
along with genes which are responsible for resistance to 
aminoglycosides and trimethoprim-sulfamethoxazole. 
Furthermore, Klebsiella pneumoniae (K. pneumoniae) 
isolates harboring ESBLs are notably more frequently 
resistant to quinolones than non-ESBL-producing strains 
and are an important cause of nosocomial infections, which 
the main population at risk is infants and immunocom-
promised hosts[3, 4].
  ESBLs occur mainly in Klebsiella species and Escherichia 
coli (E. coli) but may also exist in other members of 
Enterobacteriaceae[5]. Extended-spectrum 毬-lactamases 
(ESBLs) are the rapidly evolving group of 毬-lactamase 
enzymes, which are able to hydrolyse all cephalosporins 
and aztreonam but are inhibited by clavrulanic acid[6-10]. 
In general, most ESBLs are mutants of classical plasmid 
mediated SHV and TEM genes. ESBLs were first described 
in K. pneumoniae from Western Europe but are now widely 
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disseminated all over the world[9]. There are frequent 
reports for nosocomial outbreaks of infections caused by 
ESBL producing bacteria, but the prevalence of ESBL-
mediated resistance is not established well enough for most 
hospitals[5].
  ESBLs have a high epidemiological and clinical importance 
which are responsible for therapeutic failure and increase 
hospital costs[11]. The multidrug-resistant infections caused 
by Gram negative bacilli that produce ESBL enzymes have 
been reported with increasing prevalence of antimicrobial 
resistance in intensive-care units and are associated with 
considerable mortality and morbidity[12].
  Factors such as the transmissibility of resistance 
determinants mediated by transposons, plasmids, and gene 
cassettes in integrons along with the broad utilizations of 
antibiotics, contribute to the rise in antibiotic resistance 
in bacterial pathogens[13]. The current therapy for ESBL-
producing K. pneumonia infection is Imipenem as an 
example of broad-spectrum agent. However, there are 
several reports of therapeutic failures of this drug due to 
multiple 毬-lactamases producer strains. Owing to the 
limited therapeutic options for some of these organisms, 
the extended-spectrum 毬-lactamases producers will 
challenge clinical microbiologists and clinicians[14]. In view 
of the limited information about ICU-associated infections 
in referral hospital in Shiraz, the largest metropolis in 
south of Iran, it is necessary to understand the prevalence 
rates and pattern of such nosocomial infection to obtain 
satisfactory results in managing these infections. Therefore, 
in this study, we set up a cross-sectional study in order to 
determine the prevalence rate and phenotypic and genotypic 
characteristics of K. pneumonia infections. The molecular 
characterization of ESBL genes (TEM, SHV and CTX-M) 
from clinical isolates of K. pneumonia collected from ICU 
was carried out by Multiplex PCR. By using this method, 
the TEM, SHV and CTX-M genes could be identified 
simultaneously and characterized at molecular level[15].
2.  Materials and methods
2.1. Bacterial isolates
  A total of 60 consecutive non-repetitive clinical isolates 
of K. pneumoniae were collected from Intensive Care Units 
(ICUs) Namazi Hospital in Shiraz, Iran and were selected 
for the molecular study from the clinical samples including 
blood (n=2), urine (n=31), sputum (n=12), C.S.F (n=6), eye 
(n=3) and wound (n=6) over a 6 month period from Dec 2009 
to Jun 2010. The isolates were biochemically identified based 
on the colony morphology on Eosin Methylene Blue, Blood 
agar, Mac Conkey agar and it was speciated by standard 
biochemical tests[16]. The isolates were stored in trypticase 
soy broth with 30% glycerol at -70 曟 for further analysis.
2.2. Antibiotic susceptibility testing 
  The antibiotic susceptibility of bacteria was primarily 
carried out by the disk diffusion method using Mueller 
Hinton agar plates according to the NCCLS guidelines[18]. 
The antibiotics tested were ceftazidim, (30 毺g) , cefotaxime 
(30 毺g), cefepime (30 毺g), aztreonam (30 毺g), ampicillin (10
毺 g) , ciprofloxacin (5 毺g), gentamicin (10 毺 g), amikacin 
(30 毺g), imipenem (10 毺 g), co-trimoxazole (25 毺g)  (Hi- 
media, India). 
  Minimum inhibitory concentration (MIC) was determined 
by the E-test (AB-Biodisk, Sweden) for cefotaxime antibiotic 
based on CLSI standard procedure[17].
2.3. Screening for ESBL producing strains
  The K. pneumoniae strian was considered to have an ESBL 
phenotype if it demonstrated a reduced inhibition zone 
diameter for ceftazidime (≤22 mm) or cefotaxime (≤ 27 mm) 
or ceftriaxaone (≤ 25 mm) or aztreonam (≤ 27 mm)[9].
  The double disk synergy test (DDST) was used to screen for 
ESBL producing strains which showed resistance to one or 
more third generation cephalosporins. Cefotaxime (30 毺g),
ceftazidime (30 毺g) and aztreonam (30 毺g) were placed 
on Mueller Hinton agar plates adjacent to an amoxicillin-
clavulanic acid disk (20 毺g of amoxicillin and 10 毺g of 
clavulanic acid). The ESBL production is inferred when 
the cephalosporin inhibition zone is expanded by the 
clavulanate (≥5 mm). K. pneumoniae ATCC 700603 and
E. coli ATCC 25922 were used as positive and negative 
controls for ESBL production, respectively[18]. 
2.4. Multiplex PCR amplification 
  All isolates were screened for the resistance genes SHV, 
TEM, and CTX-M by Multiplex PCR assay using universal 
primers (Cinnagen Co, Tehran, Iran) and the detailed 
information of these primers are listed in Table 1. DNA 
extraction was performed using a heat shock method[15]. 
Initially, PCR annealing temperature gradient was performed 
and all subsequent Multiplex PCR reactions were carried 
out in a final 25 毺L volume containing 2.5 毺L of 10X PCR 
reaction buffer, 1 毺L DNA solution, 0.5毺L MgCl2 (50 mM), 
0.5 毺L of each gene-specific primer (10 pmoL), 0.5 毺L (3 
U/mL) Hot Star Taq Mastermix DNA polymerase (Qiagen) 
and 0.5 毺L deoxynucleoside triphosphates mix (dNTPs,
10 mM). PCR amplifications were performed on a MJ MINI 
DNA thermal cycler (BioRad, Australia).
  PCR amplification conditions are as follows: initial 
denaturation step at 95 曟 for 15 min: 30 cycles of 
denaturation at 94 曟 for 30 s, annealing at 60 曟 for 30 s and 
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extension at 72 曟 for 2 min followed by a final extension 
step at 72 曟 for 10 min[10]. PCR amplicons were separated 
electrophoretically on a 1% (w/w) agarose gel and stained 
with ethidium bromide. A molecular marker (Fermentase 
SMo323 100 bp DNA ladder) was used to assess PCR product 
size.
2.5. Uniplex PCR amplification of TEM, SHV, CTX-M genes 
and Sequencing 毬- lactamase genes
  In order to confirm the results obtained by the multiplex 
PCR amplification, three uniplex PCR amplification assay 
were carried out targeting the SHV, TEM and CTX-M genes, 
respectively, using 10 pmol of each gene specific primer 
as given in Table 1 and a Hot Star Taq Mastermix in a final 
reaction volume of 25 毺L. PCR amplification conditions 
are as follows: initial denaturation step at 95 曟 for 15 min, 
30 cycles of denaturation at 94 曟 for 30 s, annealing at 56 曟 
for blaSHV 50 曟 for blaTEM, and 58 曟 for blaCTX- M, extension 
at 72 曟 for 2 min, and a final extension step at 72 曟 for 10 
min. PCR amplicons were separated electrophoretically on 
1% (w/w) agarose gel and stained with ethidium bromide at a 
concentration of 20 毺g/100 mL water.
  In order to confirm and further identification of the 毬-lactamase
genes detected in PCR assays, DNA sequence analysis of the 
PCR amplicons was performed.
3. Results 
  During the study period, a total of 60 isolates of K. 
pneumonia were isolated from a range of clinical specimens 
of patients hospitalized in intensive care units of Namazi 
Hospital, Shiraz, Iran. Out of 60 isolates of K. pneumoniae 
that collected and confirmed by biochemical methods a total 
of 31 (51.67%), 12 (20%), 6 (10%), 6(10%), 3 (5%) and 2 (3.33%) 
were isolated from urine, sputum, wound, C.S.F, eye culture 
and blood, respectively.
3.1. Susceptibility test results
  The antimicrobial susceptibility test of resistant isolates 
by means of disk diffusion method showed that the least 
and most resistance were observed in imipenem (1.66%) 
and ampicilin (100%), respectively. The resistance rate to 
other antibiotics is as follow: cefotaxime (56.66%), cefepime 
(48.34%), ceftazidime (46.67%), co-trimoxazole (43.33%), 
aztreonam (31.67%), ciprofloxacin (21.66%), gentamicin 
(13.34%) and amikacine (8.34%) (Table 2). According to 
phenotypic confirmatory ESBL test; double disk synergy test 
(DDST), 60% (n=36) of K. pneumoniae isolates in our study 
was ESBL producers. Resistance to co-trimoxazole and 
ciprofloxacin among ESBL producing K. pneumoniae isolates 
were 27.78% and 16.67%, respectively. K. pneumoniae 
isolates were mainly resistant to multiple antibiotics, but 
mainly susceptible to imipenem, amikacin and gentamicin. 
The frequency of resistance among K. pneumoniae 
isolated for cefotaxime as detected by MIC E-test were in 
intermediate range (24.8 毺g/mL).
Table 2
Percentage of susceptibility and resistant antibiotics among 60 clinical 
isolates K. pneumoniae isolated from ICU. 
Antibiotics Resistant Intermediate Sensitive
Ceftazidime 28(46.67%)   4(6.66%) 28(46.67%)
Cefotaxime 34(56.66%) 10(16.67%) 16(26.67%)
Cefepime 29(48.34%)   8(13.33%) 23(38.33%)
Aztreonam 19(31.67%) 13(21.66%) 28(46.67%)
Ampicilin 60(100.00%)   0(0.00%)   0(0.00%)
Amikacin   5(8.34%)   3(5%) 52(86.66%)
Gentamicin   8(13.34%)   7(11.66%) 45(57%)
Co-trimoxazole 26(43.33%)   2(3.33%) 32(53.34%)
Ciprofloxacin 13(21.66%)   2(3.33%) 45(75%)
Imipenem 1(1.66%)   0(0%) 59(98.34%)
  The MDR phenotypes were detected in 40% (n=24) of 
K. pneumoniae isolates and was defined as resistance to 
ceftazidime, cephotaxime and cefepime and the most MDR 
strains (33.34%) were isolated from internal ICU[19]. 
3.2. Annealing temperature gradient of PCR amplification.
  A multiplex PCR amplification assay was designed to 
detect blaSHV, blaTEM, and blaCTX-M genes in ESBL suspected K. 
Table 1
Primer used for PCR and DNA sequencing.
Primer name Amplicon size (bp) Gene name Nucleotide sequence (5'-3')
TEM 445 bla-TEM-A TCGCCGCATACACTATTCTCAGAATGA
TEM 445 bla-TEM-B ACGCTCACCGGCTCCAGATTTAT
CTX-M 593 bla-CTXM-A ATGTGCAGYACCAGTAARGTKATGGC
CTX-M 593 bla-CTX-M-B TGGGT RAA RTA RGTSACCAGAA YCAGCGG
SHV 973 bla-SHV-A TCTCCCTGTTAGCCACCCTG
SHV 973 bla-SHV-B CCACTGCAGCAGCTGC(A/C)GTT
*= K is G or T, R is A or G, S is G or C, Y is C or T
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pneumoniae strains. Each PCR amplification assay created a 
unique PCR amplicon (Table 1) discernible from each other 
when separated on an appropriate agarose gel (Figure 1). PCR 
amplification of all three genes were done simultaneously, 
using a primer annealing temperature gradient between 
50 曟 and 60 曟, revealed on optimal annealing temperature 
between 58 曟 and 60 曟 (Figure 1).
Figure 1. Multiplex PCR for TEM, SHV and CTX-M: 1percent 
Agarose gel showing products of multiplex PCR amplification from 6 
clinical isolates K. pneumonae with blaTEM (445 bp), blaSHV (973 bp) 
and bla CTX-M (593 bp). 
Lane 1: The molecular size standard (100 bp) DNA ladder. Lane 2: 
TEM- CTX-M- SHV, lane 2-3-4-6-7: TEM, CTX-M. Lane 6: 
TEM.
 
3.3. Detection of blaSHV, blaTEM, blaCTX-M genes by multiplex 
PCR amplification
  The multiplex PCR assay was tested against 60 K. 
pneumoniae isolates that met and did not meet screening 
criteria. The ethidlium bromide staining of agarose gels 
revealed a distinct electrophoretic separation of the blaSHV, 
blaTEM, blaCTX-M PCR amplicons (Figure 1) 
  Result from agarose gel disclosed that the blaTEM gene alone 
was present in 38.34% (n=23) of isolates and also the similar 
rate was observed for [blaTEM, blaCTX-M] genes. The blaCTX-M 
gene alone was found in 3.33% (n=2) of isolates and the same 
for both TEM and SHV genes. Finally the three TEM, SHV, 
CTX-M genes were found in 13.33% (n=8) of isolates (Figure 
2).
  No PCR products were obtained in 3.33% (n=2) of 60 
clinical isolates, demonstrating that the blaTEM, blaCTX-M and 
blaSHV genes were either not present or that the PCR primer 
sequences may not produce any PCR products under the 
conditions used. This may be owing to single nucleotide 
sequence variations.
25
20
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Figure 2.  Prevalence extended spectrum beta lactamases genes 
among bacterial isolates K. pneumoniae isolated from ICU.
3.4. Single PCR amplification
  After initial annealing temperature optimization of the TEM, 
CTX-M and SHV primer pairs, isolated DNAs were analyzed 
for the presence of the three groups of genes of interest. The 
results achieved were in agreement with the multiplex PCR 
amplification results (data not shown).
3.5. Partial DNA sequence analysis
  DNA sequence analysis of cloned PCR amplicons derived 
from K. pneumoniae blaCTX-M and blaTEM positive strains 
confirmed the identity of the PCR amplicons as expected 
using gene - specific blaTEM, blaSHV and blaCTX-M primers.
4. Discussion 
  The emergence of ESBL-producing Gram-negative bacilli 
emphasizes on a significant mechanism of resistance 
to oxyimino-cephalosporin antibiotics. The challenges 
relating to these increasingly hostile environments have 
been ascended for their survival, and they have proved 
to be well adapted to the task. In addition, patient-to-
patient transmission is favoured by the extensive use 
of broad-spectrum antimicrobial agents at ICUs where 
antibiotic-resistant microorganisms are prevalent[20]. On 
the other hand, insufficient infection control measures 
have aggravated this problem, according to numerous 
reports of worldwide hospital outbreaks of ESBL-producing 
organisms[21]. Therefore, methods that can precisely identify 
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the potential expression or presence of these enzymes in 
clinical isolates on a large scale are thus needed. Yet, most 
ESBL detection strategies are based on determination of the 
isoelectric point (pI) and agar diffusion test methodology, 
which has usually been considered enough to identify the 
ESBL-producing strains[22]. However, in a large scale these 
methods are not the preferred options for establishing 
phenotypic identification[22]. 
  Most researchers in Iran prefer to use phenotypic methods 
along with the reported prevalence ranging from 55 to 65 per 
cent[20, 23-25]. Therefore, in the present study along with the 
phenotypic identification of ESBL-producing K. pneumoniae 
isolates, we set up Multiplex PCR as a rapid method 
for discrimination of blaTEM, blaCTX-M and blaSHV genes, 
simultaneously as well as identification of the genotypic 
pattern of these genes. The phenotype and genotype of 60 
clinical K. pneumoniae isolates, as causative nosocomial 
pathogen with high morbidity and mortality, was studied 
during 2009-2010. In this study, it was revealed that 40% 
(n=24) of isolates showed MDR phenotype. In comparison 
to other findings, Imipenem had an excellent antimicrobial 
activity against almost all MDR isolates (95.84%) followed 
by amikacin (86.11%), ciprofloxacin (80.56%)[12]. Imipenem 
and Meropenem were proposed by most investigators as 
selective drugs for ESBL-positive Entrobacteriaceae or in 
an outbreak setting. However, to maintain the therapeutic 
value of carbapenems, a fluoroquinolone or aminoglycosides 
would be preferable choice for this purpose[24]. It should be 
noted that observation of a single imipenem-resistant isolate 
in one hospital can alarm the emergence of more resistant 
isolates. Thus, there is a need for using this and other 
carbapenems with caution[23].
  The present study shows that the blaTEM was found to be 
predominant followed by blaCTX-M and blaSHV, respectively. 
These findings are in agreement with those of recent studies 
in several cities of Iran that had similar pattern of ESBLs 
distribution[23-25]. However, this pattern is different from 
that of other countries (e.g. Italy, Egypt and Austria), which 
CTX-M is the most of 毬-lactamases[26, 27].
  In conclusion, this study highlights the importance of high 
emergence of ESBLs in Iran with the rate of 60%, which is 
an alarm to be more aggravated if this trend continued due 
to lack of rational drug administration policy. Therefore, 
attempts to keep up current therapeutic options for ESBL 
producing bacteria by limiting the use of extended spectrum 
antibacterial agents and 3rd generation cephalosporins 
along with implementation of infection control measures are 
crucial. This study also provides the Multiplex PCR could be 
a simple and fast alternative procedure for an efficient, rapid 
discrimination of ESBLs in K. pneumoniae as well as a rapid 
tool for epidemiological studies among ESBL isolates.
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